On January 13, 2016 Sirio Pharma sold its subsidiary company, Treerly Health Co., Ltd and its Treerly brand to Pfizer, the world’s largest pharmaceutical company.
Sirio has been providing Pfizer with product development and contract manufacturing services since 2012. The 10 year old Treerly brand has grown to become one of the top 10 health brands in China’s retail market. Treerly has established an outstanding reputation in the market for providing a superior mix of innovative women’s products. Pfizer’s purchase of Treerly will help enhance their market position in China’s nutrition and healthcare marketplace.
“The acquisition of the Treerly brand and its family of products will enhance the portfolio of dietary supplements we offer to our retail customers in China and will enable us to help more consumers improve their health and well-being,” said Keith Choy, regional president, Asia Pacific, Pfizer Consumer Healthcare. “The addition of the Treerly products will also make it possible to leverage our existing sales and marketing capabilities and be more efficient in launching future innovations for consumers in China,” he said.
In the agreement, Sirio Pharma will continue to supply Pfizer with the full range of Treerly products. The pillars that strengthened this partnership are Sirio’s robust quality processes, experienced and creative R&D team, capacity and the latest testing and instrument technology. Selling 100% stake to Pfizer is one part of the agreement between Sirio and Pfizer representing a new milestone of both organizations’ strategic partnership.
In the next decade, Sirio will embark on a more comprehensive partnership with Pfizer focusing in the areas of research and development, manufacturing, and supplying nutritional foods. Both organizations are excited about the future growth of the Treerly brand. We wish Pfizer continued success.
Sirio Pharma will continue focusing on bringing innovative products to the global marketplace that meet our mission of delivering value for health to consumers around the world.
Sirio Pharam Co., Ltd (Sirio Pharma ) is one of the world’s largest CDMOs located in China for dietary supplements including softgel, capsule, tablet, powder, gummy and oral liquid dosage forms.
Sirio is among the very few contract manufacturers who are committed to active R&D, and offering its customers one-stop solution including developing, manufacturing, packaging and logistics since 1993.
And its world-class quality level is approved by TGA’s GMP, NPA cGMP, GMP for Health Foods by SFDA , BRC certification, and etc.
Cooperating with world’s top pharmaceutical companies, Sirio is committed to delivering value to health for customers all over the world.
For more information, visit Sirio’s website at www.siriopharma.com